Rein Therapeutics, Inc. Common Stock (RNTX) Q1 2026 Annual Earnings
RNTX·Reported May 15, 2026·Before market open
Diluted EPS came in at $-0.19 (+26.9% YoY), beat the $-0.49 consensus by $0.30.
Diluted EPS
$-0.19beat by $0.30
Consensus: $-0.49
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about Rein Therapeutics, Inc. Common Stock's Q1 2026 earnings report.
Rein Therapeutics, Inc. Common Stock (RNTX) reported Q1 2026 earnings on May 15, 2026 before market open.
Rein Therapeutics, Inc. Common Stock reported diluted EPS of $-0.19 for Q1 2026.
EPS beat the consensus estimate of $-0.49 by $0.30.
Compared to the same quarter a year prior, diluted EPS grew 26.9% from $-0.26.
You can read the 10-K/A periodic report (0001193125-26-178787) directly on SEC EDGAR. The filing index links above go to sec.gov.